1-6 of 6
John M. Pagel
Close
Sort by
Journal Articles

Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study

Clinical Trials & Observations
Gareth P. Gregory, Shaji Kumar, Ding Wang, Daruka Mahadevan, Patricia Walker, Nina Wagner-Johnston, Carolina Escobar, Rajat Bannerji, Divaya Bhutani, Julie Chang, Francisco J. Hernandez-Ilizaliturri, Andreas Klein, John M. Pagel, Witold Rybka, Andrew J. Yee, Anne Mohrbacher, Mo Huang, Mohammed Farooqui, Patricia Marinello, Hang Quach
Journal: Blood Advances
Blood Adv (2022) 6 (4): 1232–1242.
https://doi.org/10.1182/bloodadvances.2021005872
Published: 2022
Includes: Supplemental data
Journal Articles

Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies

Clinical Trials & Observations
Matthew S. Davids, Owen A. O’Connor, Wojciech Jurczak, Felipe Samaniego, Timothy S. Fenske, Pier Luigi Zinzani, Manish R. Patel, Nilanjan Ghosh, Bruce D. Cheson, Enrico Derenzini, Danielle M. Brander, James A. Reeves, Wanda Knopińska-Posłuszny, John N. Allan, Tycel Phillips, Paolo F. Caimi, Ewa Lech-Maranda, John M. Burke, Richy Agajanian, Ruth Pettengell, Lori A. Leslie, Chan Y. Cheah, Gustavo Fonseca, James Essell, Julio C. Chavez, John M. Pagel, Jeff P. Sharman, Yanzhi Hsu, Hari P. Miskin, Peter Sportelli, Michael S. Weiss, Ian W. Flinn
Journal: Blood Advances
Blood Adv (2021) 5 (23): 5332–5343.
https://doi.org/10.1182/bloodadvances.2021005132
Published: 2021
Includes: Supplemental data
Journal Articles

Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome

Clinical Trials & Observations
Je-Hwan Lee, Stefan Faderl, John M. Pagel, Chul Won Jung, Sung-Soo Yoon, Animesh D. Pardanani, Pamela S. Becker, Howard Lee, Jeongeun Choi, Kyoungjune Lee, Minkyoung Kim, Jorge E. Cortes
Journal: Blood Advances
Blood Adv (2020) 4 (9): 2032–2043.
https://doi.org/10.1182/bloodadvances.2019000757
Published: 2020
Includes: Supplemental data
Journal Articles

A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD–mutant acute myeloid leukemia

Clinical Trials & Observations
Catherine C. Smith, Mark J. Levis, Olga Frankfurt, John M. Pagel, Gail J. Roboz, Richard M. Stone, Eunice S. Wang, Paul L. Severson, Brian L. West, Mai H. Le, Sabine Kayser, Bao Lam, Henry H. Hsu, Chao Zhang, Gideon Bollag, Alexander E. Perl
Journal: Blood Advances
Blood Adv (2020) 4 (8): 1711–1721.
https://doi.org/10.1182/bloodadvances.2020001449
Published: 2020
Includes: Supplemental data
Journal Articles

A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL

Clinical Trials & Observations
Anthony R. Mato, Lindsey E. Roeker, Toby A. Eyre, Chadi Nabhan, Nicole Lamanna, Brian T. Hill, Danielle M. Brander, Paul M. Barr, Frederick Lansigan, Bruce D. Cheson, Arun K. Singavi, Maryam Sarraf Yazdy, Nirav N. Shah, John N. Allan, Erica B. Bhavsar, Joanna Rhodes, Kaitlin Kennard, Stephen J. Schuster, AnnaLynn M. Williams, Alan P. Skarbnik, Andre H. Goy, Julie M. Goodfriend, Colleen Dorsey, Catherine C. Coombs, Hande Tuncer, Chaitra S. Ujjani, Ryan Jacobs, Allison M. Winter, John M. Pagel, Neil Bailey, Anna Schuh, Mazyar Shadman, Andrea Sitlinger, Hanna Weissbrot, Sivraj Muralikrishnan, Andrew Zelenetz, Amy A. Kirkwood, Christopher P. Fox
Journal: Blood Advances
Blood Adv (2019) 3 (10): 1568–1573.
https://doi.org/10.1182/bloodadvances.2019000180
Published: 2019
Journal Articles

Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib

Clinical Trials & Observations
Farrukh T. Awan, Anna Schuh, Jennifer R. Brown, Richard R. Furman, John M. Pagel, Peter Hillmen, Deborah M. Stephens, Jennifer Woyach, Elena Bibikova, Prista Charuworn, Melanie M. Frigault, Ahmed Hamdy, Raquel Izumi, Bolan Linghu, Priti Patel, Min Hui Wang, John C. Byrd
Journal: Blood Advances
Blood Adv (2019) 3 (9): 1553–1562.
https://doi.org/10.1182/bloodadvances.2018030007
Published: 2019